Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

As the Trump administration executes its plan to impose tariffs on certain countries and specific industries and goods, financial markets have responded with volatility. Among the uncertainty, and with other factors also impacting stock indices, the S&P 500 is down 4% year to date. The longer-term impact on corporate America, consumers, and the overall economy is not yet clear. Markets have proven over time that they don't like uncertainty. Companies reporting at the end of the current earnings cycle have had more time to assess the potential impact of tariffs, and some have added line items to account for possible related pressure on profits. As we see it, one investing strategy is to avoid the whole headwind by turning to industries that we think are relatively immune to trade-talk risk. These include groups that are more focused on domestic markets, such as certain utilities, regional banks, restaurants, retailers, and stock exchanges (which should benefit from increased trading activity). Up on the sector level, we believe that Healthcare companies are well shielded. For this week's list, we highlight Healthcare companies that should feel little or no impact from tariffs and likely are safe havens from the potential imposition of tariffs on imports. These businesses focus primarily on the U.S. market and have solid growth profiles and strong balance sheets, enabling them to invest for future growth. They also benefit from the demographics of an aging population that engages in higher utilization of healthcare, driving up volumes of prescription drugs and diagnostic tests and increasing the need to manage healthcare benefits. They also have outperformed the broader market year-to-date. Here are some Argus BUY-rated Healthcare stocks that we feel offer a safe haven from tariffs.

Headquartered in Conshohocken, Pennsylvania, Cencora, formerly AmerisourceBergen, is one of the nation's largest pharmaceutical distributors. The company distributes brand name and generic pharmaceuticals, over-the-counter (OTC) healthcare products, and home healthcare supplies and equipment to healthcare providers throughout the U.S. It also provides pharmaceuticals and pharmacy services to patients requiring specialty drugs such as immunology and oncology treatments. Cencora has international operations through its World Courier logistics business and assets acquired from Alliance Healthcare.